FACULTY
Tahseen Mozaffar, MD
Professor of Neurology and Pathology
Director, Division of Neuromuscular Medicine
Director, UC Irvine-MDA ALS and Neuromuscular Center
Department of Neurology
University of California, Irvine
Orange, California
PROGRAM OVERVIEW
This educational activity is designed to equip providers managing patients with late-onset Pompe disease (LOPD) with essential skills for prompt diagnosis, developing treatment plans with advanced enzyme replacement therapy (ERT), and effective clinical monitoring. including strategies for ERT transitions. Through a case study–based format, participants will access practical point-of-care resources, including a personalized poster generation portal.
TARGET AUDIENCE
This activity is designed to meet the educational needs of neuromuscular specialists, geneticists, neurologists, lysosomal disease specialists, genetic counselors, pediatricians, and other healthcare professionals who have a role in the management of patients with Pompe disease.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Summarize the appropriate methodology for prompt diagnosis of LOPD based on clinical suspicion, including genetic testing
- Analyze clinical efficacy and tolerability data in constructing treatment plans using novel, next generation ERTs
- Apply multidisciplinary clinical monitoring management strategies to ensure optimal therapeutic benefits are rendered, including ERT switching strategies
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 1.0 ANCC contact hour.
ACCME INNOVATION PARTNER
Med Learning Group (MLG) is proud to be recognized as an ACCME Innovation Partner, leading the way in simplifying CME for physicians. As an Innovation Partner, MLG will be working with the ACCME by submitting credits directly to CME Passport.
PHYSICIAN DISCLAIMER: Upon your acceptance in the evaluation and completion of this CME activity, Med Learning Group will share your completion information and certain personal details (e.g., name, National Provider Identifier, birthdate MM/DD) with the ACCME for inclusion in your CME Passport transcript and, as applicable, reporting to certifying, licensing, or other regulatory authorities you specify.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Speaker | Relationships | Manufacturer |
| Tahseen Mozaffar, MD | Consultant | Amicus Therapeutics, Sanofi, Aro Biotherapeutics, Creyon Bio, Maze Therapeutics, Shionogi, and Regeneron Pharmaceuticals |
| Speakers Bureau | Sanofi, Argenx | |
| Contracted research | Amicus Therapeutics, Sanofi, Aro Biotherapeutics, and Astellas Gene Therapies |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, CEO of Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, Sr VP of Operations for Med Learning Group, has nothing to disclose.
- Sharine Griggs, Senior Program Manager for Med Learning Group, has nothing to disclose.
- Tom Bregartner, MBA, VP of Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Surabhi Dangi-Garimella, Ph.D., Medical Director for Med Learning Group has nothing to disclose.
- Sarah Milano RN, MSN, has nothing to disclose.
- A medical reviewer from CME Peer Review LLC, has nothing to disclose.
- Russie Allen, Accreditation and Outcomes Manager for Med Learning Group, has nothing to disclose.
- Emmanuella Foucault, Associate Program Manager for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
ACCME INNOVATION PARTNER DISCLAIMER
Upon your acceptance in the evaluation and completion of this CME activity, Med Learning Group will share your completion information and certain personal details (eg, name, National Provider Identifier, birthdate MM/DD) with the ACCME for inclusion in your CME Passport transcript and, as applicable, reporting to certifying, licensing, or other regulatory authorities you specify.
RELEASED DATE: November 21, 2025
EXPIRATION DATE: November 21, 2026
Copyright © 2025 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
